[ 64 Cu]Cu-NOTA-EV-F(ab′) 2 Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.270132 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Wenpeng Huang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Copper Radioisotopes, Cell Adhesion Molecules, Urinary Bladder Neoplasms, Triple Negative Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Our study aimed to develop and evaluate [64Cu]Cu-NOTA-EV-F(ab')2 for immuno-PET imaging of nectin-4 expression in triple-negative breast cancer (TNBC) and urothelial bladder cancer (UBC) models, with the goal of achieving rapid, specific tumor targeting and high tumor-to-background contrast. Methods: Bivalent antibody fragments were generated from enfortumab vedotin (EV) using IdeS protease and conjugated with NOTA for radiolabeling with 64Cu. In vitro binding and uptake studies were performed using TNBC and UBC cell lines. Immuno-PET imaging and biodistribution studies were conducted in athymic nude mice bearing subcutaneous xenografts with varying nectin-4 expression. Results: [64Cu]Cu-NOTA-EV-F(ab')2 exhibited rapid tumor accumulation and high specificity in nectin-4-positive tumors, with peak uptake observed at 4 h after injection. EV-F(ab')2 demonstrated superior tumor-to-background ratios compared with the full-length EV antibody, particularly in nectin-4-expressing models (MDA-MB-468, BT474, SW780, and HT-1376). Blocking studies confirmed nectin-4-specific targeting. Favorable pharmacokinetics of EV-F(ab')2 allowed for same-day imaging and reduced radiation exposure relative to intact antibodies. Conclusion: [64Cu]Cu-NOTA-EV-F(ab')2 is a promising immuno-PET probe for assessing nectin-4 expression in TNBC and UBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin.
- Department of Radiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; and.
- Department of Nuclear Medicine, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
- Department of Nuclear Medicine, Peking University First Hospital, Beijing, China; wcai@uwhealth.org kanglei@bjmu.edu.cn.
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, Wisconsin; wcai@uwhealth.org kanglei@bjmu.edu.cn.
Förderung
- NCI NIH HHS
Zitieren
APA
Huang, W., Li, L., Chao, F., Yang, Q., Mixdorf, J. C., Engle, J. W., Hsu, J. C., Kang, L., & Cai, W. (2025). [ 64 Cu]Cu-NOTA-EV-F(ab′) 2 Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270132
Vancouver
Huang W, Li L, Chao F, Yang Q, Mixdorf JC, Engle JW, et al. [ 64 Cu]Cu-NOTA-EV-F(ab′) 2 Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270132
BibTeX
@article{Huang2025,
author = {Huang, Wenpeng and Li, Liming and Chao, Fangfang and Yang, Qi and Mixdorf, Jason C and Engle, Jonathan W and Hsu, Jessica C and Kang, Lei and Cai, Weibo},
title = {[ 64 Cu]Cu-NOTA-EV-F(ab′) 2 Enables Same-Day Immuno-PET Imaging of Nectin-4 in Triple-Negative Breast and Urothelial Bladder Cancers},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.270132}
}
EUVIMED